Phibro Animal Health Becomes a Powerhouse in Animal Health after Zoetis Deal!
Reading Time: 3 minutes
In a favorable market environment, there are robust investments in animal health. Phibro is well positioned with vaccines, feed additives, and medications. The successful integration of the Zoetis MFA portfolio makes Phibro the world's second-largest provider. The "Phibro Forward" initiative aims to improve margins starting from 2027. Restoris, a gel for the treatment of periodontal disease in dogs, addresses the pet market and is seen as a long-term fourth key pillar. Phibro Animal Health (PAHC) operates as a global leader in the development...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
